# XBiotech Inc.: Form 10-Q for the period ended Jun 30, 2017

- Company: [XBiotech Inc.](/companies/xbit.md) (CIK 1626878)
- Form: 10-Q
- Filed: 2017-08-08
- Accepted by EDGAR: Aug 8, 2017, 16:51 ET
- Period: 2017-06-30
- Accession: 0001171843-17-004856
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1626878/000117184317004856/f10q_080817p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1626878/000117184317004856/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $15.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$9.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$20.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$9.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$19.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.26 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.57 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $890.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-06-30 | $45.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $47.3m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $77.8m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $4.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $4.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-06-30 | $73.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,273 characters.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

We have never been profitable and, as of June 30, 2017, we had an accumulated deficit of $203.1 million. We had net losses of $9.1 million and $19.7 million for the three months and six months ended June 30, 2017, respectively, compared to $13.6 million and $23.9 million for the three months and six months ended June 30, 2016, respectively. We expect to incur significant operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of June 30, 2017, we had 60 employees compared to 103 as of March 31, 2017. This decrease was due to a re-orgainization of the Company that occurred following the recent material events surrounding the Phase 3 oncology studies.

### Recent Events:

### Clinical Regulatory Developments

The Company’s Phase III symptomatic colorectal cancer study has been completed and XBiotech proceeded with the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in March 2016. In May 2017, the Company announced that it received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) for the MAA in Europe. XBiotech is proceeding with the EMA’s re-examination procedure in which new Rapporteurs will be assigned to reevaluate the initial opinion. The Company has retained European counsel and regulatory specialists in Europe to manage the re-examination process, who is following the standard protocol and timetable set by the EMA.

In June 2017 XBiotech reported discontinuation of its second Phase III study, a double-blind placebo controlled study for improving survival in metastatic colorectal cancer, following the Independent Data Monitoring Committee’s (IDMC) second prospectively planned, unblinded interim analysis at 75% of events in the study. The IDMC had no safety concerns from the unblinded analysis. However, the committee recommended the early termination of the study since the findings were not sufficient to meet efficacy or the threshold for continuation, which involved a prospectively defined acceptance boundary for the interim analysis. XBiotech is currently conducting full data analyses, as stratification of the data may identify subpopulations that benefited from therapy.

Based on the positive, top-line results announced earlier this year in two Phase II studies, one which evaluated MABp1 for the treatment of Hidradenitis Suppurativa and one using the Company’s proprietary 514G3 True Human antibody for the treatment of *Staphylococcus aureus* bloodstream infections, plans for advanced studies in these indications is on-going. We are seeking end of Phase 2 meetings with the FDA to help guide the development of special protocol asssessments (SPA), which are submitted to the FDA to enable better agreement on what will be sufficient data to seek product registration.

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $45.9 million at June 30, 2017 will enable the Company to achieve several major inflection points, including potential marketing authorization in Europe depending on the outcome of the re-examination procedure, advanced clinical studies in certain indication(s), as well as on-going R&D efforts for the Company’s pre-clinical pipeline. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of June 30, 2017 will enable us to fund our operating expenses and capital expenditure requirements through 2018. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

### Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.

### Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through June 30, 2017, we have recorded total research and development expenses, including share-based compensation, of $159.2 million. Our total research and development expenses for the three months and six months ended June 30, 2017 were $7.4 million and $15.6 million, respectively, compared to $11.2 million and $19.0 million for the three months and six months ended June 30, 2016, respectively. Share-based compensation accounted for ($0.3) million and $21 thousand for the three months and six months ended June 30, 2017, respectively, compared to $0.6 million and $1.2 million for the three months and six months ended June 30, 2016, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months and six months ended June 30, 2017 were 76% and 78%, respectively, compared to 82% and 80% for the three months and six months ended June 30, 2016, respectively. The percentages, *excluding* stock-based compensation, for the three months and six months ended June 30, 2017 were 87% and 85%, respectively, compared to 88% and 87% for the three months and six months ended June 30, 2016, respectively.

The clinical research and development costs may decrease going forward with the completion of all clinical studies to date. Although, expenses could increase due to potential marketing approval of our lead product candidate in Europe based on the outcome of the re-examination procedure and related commercialization costs, as well as, the potential of pursuing advanced clinical studies in various indications.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

### General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months and six months ended June 30, 2017 were $2.3 million and $4.4 million, respectively, compared to $2.4 million and $4.8 million for the three months and six months ended June 30, 2016, respectively. Share-based compensation accounted for $1.2 million and $1.6 million for the three months and six months ended June 30, 2017, respectively, compared to $0.5 million and $1.7 million for the three months and six months ended June 30, 2016, respectively.

General and administrative expenses, as a percentage of total operating expenses for the three months and six months ended June 30, 2017 were 24% and 22%, respectively, compared to 18% and 20% for the three months and six months ended June 30, 2016, respectively. The percentages, *excluding* stock-based compensation, for the three months and six months ended June 30, 2017 were 13% and 15%, respectively, compared to 15% and 15% for the three months and six months ended June 30, 2016, respectively.

### Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2016.

### Results of Operations

### Revenue

We did not record any revenue during the three months and six months ended June 30, 2017 and 2016.

### Expenses

#### Research and Development

Research and Development costs are summarized as follows (in thousands):

|  | Three Months Ended June 30, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $1,770 | $1,980 | $(211) | (11%) |
| Laboratory and manufacturing supplies | 780 | 2,762 | (1,982) | (72%) |
| Clinical trials and sponsored research | 3,785 | 4,657 | (872) | (19%) |
| Stock-based compensation | (273) | 587 | (860) | (147%) |
| Other | 1,337 | 1,230 | 108 | 9% |
| Total | $7,399 | $11,216 | $(3,817) | (34%) |

|  | Six Months Ended June 30, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $3,983 | $3,837 | $146 | 4% |
| Laboratory and manufacturing supplies | 2,012 | 3,538 | (1,526) | (43%) |
| Clinical trials and sponsored research | 6,941 | 8,313 | (1,372) | (17%) |
| Stock-based compensation | 21 | 1,184 | (1,163) | (98%) |
| Other | 2,630 | 2,156 | 474 | 22% |
| Total | $15,587 | $19,028 | $(3,441) | (18%) |

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses decreased by 34% to $7.4 million for the three months ended June 30, 2017 compared to $11.2 million for the three months ended June 30, 2016. Research and development expenses decreased by 18% to $15.6 million for the six months ended June 30, 2017 compared to $19.0 million for the six months ended June 30, 2016.

The three month decrease in research and development expenses was mainly due to a $2.0 million decrease in laboratory and manufacturing supplies expense, due to a reduction in clinical trial drug manufacturing. In addition there was a decrease in clinical trials and sponsored research expense due to the slow down of a global trial. Stock-based compensation expenses also decreased due to the forfeiture of terminated employees’ stock option.

Compared to the six months ended June 30, 2016, the research and development expense decrease in the six months ended June 30, 2017 was primarily caused by the decrease in laboratory and manufacturing supplies expense. The clinical trials and sponsored research expense decrease was principally due to the reduced expense accrual and as a result of the slow down of a global trial.

#### General and Administrative

General and administrative costs are summarized as follows (in thousands):

|  | Three Months Ended June 30, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $297 | $386 | $(89) | (23%) |
| Patent filing expense | 171 | 207 | (36) | (17%) |
| Stock-based compensation | 1,171 | 511 | 660 | 129% |
| Professional fees | 312 | 768 | (456) | (59%) |
| Other | 338 | 527 | (189) | (36%) |
| Total | $2,289 | $2,399 | $(110) | (5%) |

|  | Six Months Ended June 30, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $765 | $913 | $(148) | (16%) |
| Patent filing expense | 357 | 353 | 4 | 1% |
| Stock-based compensation | 1,601 | 1,730 | (129) | (7%) |
| Professional fees | 728 | 860 | (132) | (15%) |
| Other | 921 | 979 | (58) | (6%) |
| Total | $4,372 | $4,835 | $(463) | (10%) |

General and administrative expenses decreased by 5% to $2.3 million for the three months ended June 30, 2017 compared to $2.4 million for the three months ended June 30, 2016. General and administrative expenses decreased by 10% to $4.4 million for the six months ended June 30, 2017 compared to $4.8 million for the six months ended June 30, 2016.

The three months decrease was primarily related to a $0.5 million decrease in public relations fees and legal fees. Other expenses also decreased including travel and recruiting activities. Stock-based compensation increased $0.7 million due to the repurchase of stock options from a certain individual.

The six months decrease was principally due to the decrease in stock-based compensation, the reduction of our workforce and the public relations fees. The decrease in stock-based compensation is due to the grant of stock options to board members in 2016 Q1 that were immediately vested. Labor costs also decreased due to the reduction of our general and administrative workforce from 11 to 5.

### Other income (loss)

The following table summarizes other income (loss) (in thousands):

|  | Three Months Ended June 30, 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Interest income | 114 | - | 164 | - |
| Foreign exchange gain (loss) | 441 | (7) | 99 | (16) |
| Total | $555 | $(7) | $263 | $(16) |

The interest income for the three months and six months ended June 30, 2017 is mainly from the interest generated from our Canadian bank account. Foreign exchange gain was mainly due to the fluctuation of the exchange rate between Euro and US dollar.

### Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through June 30, 2017, we have funded our operations principally through public offerings and private placements of equity securities, which have provided aggregate cash proceeds of approximately $289.9 million. The following table summarizes our sources and uses of cash (in thousands):

| Net cash (used in) provided by: | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: |
| Operating activities | $(20,376) | $(18,198) |
| Investing activities | (890) | (8,774) |
| Financing activities | 33,274 | 707 |
| Effect of foreign exchange rate on cash and cash equivalents | (383) | 12 |
| Net change in cash and cash equivalents | $11,625 | $(26,253) |

During the six months ended June 30, 2017 and 2016, our operating activities used net cash of $20.4 million and $18.2 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The net loss from operations for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016 decreased, but the prepayment for clinical trial and payment for bills related to previous period expense increased the cash used.

During the six months ended June 30, 2017 and 2016, our investing activities used net cash of $0.9 million and $8.7 million, respectively. The use of cash during the six months ended June 30, 2017 was for the purchase of new research and development equipment. We spent approximately $8.8 million on the construction of new facilities during the six months ended June 30, 2016.

During the six months ended June 30, 2017 and 2016, our financing activities provided net cash proceeds of $33.3 million and $0.7 million, respectively. During the six months ended June 30, 2017, we entered into subscription agreements with accredited investors, and sold 2.4 million common shares at $13 per share for approximately $31.6 million in net proceeds. Also, we sold 87 thousand shares under a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC for net proceeds of approximately $1.0 million. Employees exercised stock options to purchase a total of 271 thousand shares of common stock for a total of approximately $0.8 million in net proceeds. During the six months ended June 30, 2016, employees exercised stock options to purchase a total of 150 thousand shares of common stock for a total of approximately $0.7 million in net proceeds.

We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the Food and Drug Administration or similar regulatory agencies in other countries and successfully commercialized. As of June 30, 2017, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $45.9 million.

### Contractual Obligations and Commitments

On January 12, 2008, we entered a lease agreement to lease our facility in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2014, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. On February 28, 2016, we extended the lease for another 4 years. The future minimum lease payments are as follows as of June 30, 2017 (in thousands):

| Contractual Obligations | Total | Less than 1 Year | 1 - 3 Years | More than 3 years |
| --- | ---: | ---: | ---: | ---: |
| Operating facility leases | $780 | $465 | $315 | $— |
| Total contractual obligations | $780 | $465 | $315 | $— |

Rent expense was $186 thousand and $180 thousand for the three months ended June 30, 2017 and 2016, respectively.

### Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

## Market risk

As filed, 308 characters.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

## Controls and procedures

As filed, 1,805 characters.

### Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the second quarter of the year ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 837 characters.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2016. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.

Filed Aug 8, 2017.
Source: SEC EDGAR, the filing index for accession 0001171843-17-004856. Last ingested by Listed: Nov 14, 2026, 18:14 ET. No prices; not investment advice.
